Zentalis Pharmaceuticals (ZNTL) Cash from Financing Activities (2019 - 2026)

Zentalis Pharmaceuticals has reported Cash from Financing Activities for 8 years, with the latest figure at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities fell 694.18% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$5.6 million (down 2028.97% YoY), and the FY2025 full-year result was -$4.3 million, down 4064.81% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$1.1 million, up from -$4.6 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $236.6 million in Q2 2023, with the low at -$4.6 million in Q4 2025.
• Average Cash from Financing Activities over 5 years is $35.2 million, with a median of $249000.0 recorded in 2023.
• Year-over-year, Cash from Financing Activities surged 66383.23% in 2022 and slumped 694.18% in 2026.
• Tracing ZNTL's Cash from Financing Activities over 5 years: stood at $49.7 million in 2022, then plunged by 99.38% to $309000.0 in 2023, then tumbled by 70.23% to $92000.0 in 2024, then sank by 5084.78% to -$4.6 million in 2025, then surged by 75.51% to -$1.1 million in 2026.
• The last three Cash from Financing Activities figures came in at -$1.1 million (Q1 2026), -$4.6 million (Q4 2025), and $115000.0 (Q3 2025), per Business Quant data.

Peer Comparison